The Zhitong Finance App learned that J.P. Morgan Chase is further revising expectations for LLY.US (LLY.US)'s profit growth over the next few years. The research team led by analyst Chris Schott reaffirmed Eli Lilly's “overrated” (Overrated) rating and the bank's “preferred stock” status, and raised the target price from $1,500 to $1,650 in December 2027. There is still room for about 20.1% increase from the closing price of $1373.70 on October 29. The bank is optimistic not only about the current strong growth in diet drug sales, but also the long-term growth space brought about by the expansion of overseas markets, the increase in the penetration rate of obesity treatment in the US, and the relaying of new oral products. At a time when the AI capital expenditure cycle triggers the market to re-examine the valuation of technology stocks and the ability to deliver profits, Eli Lilly is becoming another main line of growth that Wall Street is focusing on.

The Zhitong Finance App learned that J.P. Morgan Chase is further revising expectations for LLY.US (LLY.US)'s profit growth over the next few years. The research team led by analyst Chris Schott reaffirmed Eli Lilly's “overrated” (Overrated) rating and the bank's “preferred stock” status, and raised the target price from $1,500 to $1,650 in December 2027. There is still room for about 20.1% increase from the closing price of $1373.70 on October 29. The bank is optimistic not only about the current strong growth in diet drug sales, but also the long-term growth space brought about by the expansion of overseas markets, the increase in the penetration rate of obesity treatment in the US, and the relaying of new oral products. At a time when the AI capital expenditure cycle triggers the market to re-examine the valuation of technology stocks and the ability to deliver profits, Eli Lilly is becoming another main line of growth that Wall Street is focusing on.